1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

In Brief: FTC, FDA Enforcement; Insider Trading On NBTY Sale; Comment Period On Label Changes

 
• By Elizabeth Crawford

FTC says Pure Green Coffee perks false claims; NBTY shareholder settles insider trading case; scientific citations trigger warning letter; supplement labels must detail plant source; scientific citations trigger warning; and more news In Brief.

The Federal Trade Commission alleges NBP Advertising Inc.’s Pure Green Coffee business makes false claims about a self-named supplement and creates fake blogs and news sites to promote the weight loss product, according to a May 19 announcement. In addition, NBP misappropriated logos from actual news organizations, including CNN, to confuse consumers about whether they are viewing an advertisement or news piece, according to FTC’s complaint filed in the U.S. District Court for the Middle District of Florida, Tampa Division. The commission also notes the Tampa-based firm failed to disclose it paid endorsers for video testimonials and provided them free product. The allegations recall an enforcement blitz that FTC brought against at least 10 affiliate marketers of acai supplements in 2011 for faking news investigations to advertise their supplements Also see "FTC Continues Acai Crackdown With Blitz Against Affiliate Marketers" - Pink Sheet, 25 April, 2011..

A former [NBTY Inc.] board member and some of his family members agree to pay $500,000 to resolve allegations of insider trading brought by the Securities and Exchange Commission. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

US FDA’s ‘Good Reputation’ For Science May Mean Loper Bright Not ‘Cataclysmic,’ Attorney Says

 
• By Malcolm Spicer

Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

What Information Does US FDA Need For Stealth’s Elamipretide After CRL?

 
• By Sue Sutter

The agency said it will consider knee extensor muscle strength as a potential intermediate clinical endpoint to support accelerated approval, but Stealth CEO Reenie McCarthy said announcing it via complete response letter is confusing and inefficient.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

More from North America

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.